Growth Metrics

Eli Lilly (LLY) Receivables - Net (2016 - 2026)

Eli Lilly filings provide 18 years of Receivables - Net readings, the most recent being $18.4 billion for Q1 2026.

  • On a quarterly basis, Receivables - Net rose 53.11% to $18.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $18.4 billion, a 53.11% increase, with the full-year FY2025 number at $17.8 billion, up 61.37% from a year prior.
  • Receivables - Net hit $18.4 billion in Q1 2026 for Eli Lilly, up from $17.8 billion in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $18.4 billion in Q1 2026 to a low of $6.3 billion in Q1 2022.
  • Median Receivables - Net over the past 5 years was $9.1 billion (2023), compared with a mean of $10.4 billion.
  • Biggest five-year swings in Receivables - Net: grew 3.34% in 2022 and later soared 61.37% in 2025.
  • Eli Lilly's Receivables - Net stood at $6.9 billion in 2022, then skyrocketed by 31.82% to $9.1 billion in 2023, then grew by 21.07% to $11.0 billion in 2024, then soared by 61.37% to $17.8 billion in 2025, then grew by 3.77% to $18.4 billion in 2026.
  • The last three reported values for Receivables - Net were $18.4 billion (Q1 2026), $17.8 billion (Q4 2025), and $16.1 billion (Q3 2025) per Business Quant data.